India · Pregnancy · Megaloblastic Anaemia · NTD Prevention · MTX Rescue · Folvite · Fefol
🚫 Never treat megaloblastic anaemia with folate alone without ruling out B12 deficiency — folate corrects blood picture but worsens B12-related neurological damage (SACD).
⚠️ High-dose folic acid (≥5mg/day) may reduce anticonvulsant efficacy in epilepsy — use with caution.
💊 Folinic acid (leucovorin) ≠ folic acid — do NOT substitute in MTX rescue protocols.
Folic acid (Vitamin B9) deficiency is one of the most clinically significant micronutrient deficiencies in India, particularly among women of reproductive age, pregnant women, and patients on anti-folate drugs. India has among the highest rates of neural tube defects (NTDs) globally — approximately 4–8 per 1000 live births — and periconceptional folic acid supplementation is the single most effective preventive intervention.
All women planning pregnancy should take folic acid 400–500 mcg/day starting at least one month before conception and continuing through the first trimester. High-risk women — those with a prior NTD-affected pregnancy, epilepsy on anticonvulsants, pre-existing diabetes, or BMI >30 — require a higher dose of 5 mg/day (Folvite 5mg), starting 3 months before conception. Under India's Weekly Iron and Folic Acid Supplementation (WIFS) programme, adolescent girls and pregnant women receive government-supplied IFA tablets containing 500 mcg folic acid + 100 mg elemental iron.
Before treating megaloblastic anaemia with folic acid, B12 deficiency must be excluded — this is a critical clinical rule. Folate treatment corrects the haematological picture of B12 deficiency (macrocytic anaemia) but does not treat, and may unmask or worsen, B12-related neurological complications including subacute combined degeneration of the cord (SACD). Once B12 deficiency is excluded, folate deficiency anaemia is treated with folic acid 5 mg orally once daily for 4 months.
Low-dose MTX (for RA, psoriasis, JIA): folic acid 5 mg once weekly, taken 24–48 hours after the MTX dose, reduces GI side effects and hepatotoxicity without reducing efficacy. High-dose MTX (for cancers): requires folinic acid (leucovorin / calcium folinate) rescue — not folic acid — starting 24 hours after MTX infusion. These two situations are frequently confused in practice. Folinic acid bypasses the DHFR enzyme that MTX inhibits; folic acid does not.
| Indication | Dose | Duration | Guideline |
|---|---|---|---|
| Routine pregnancy / TTC | 400–500 mcg/day | Preconception + 1st trimester | WHO / FOGSI |
| High-risk (prior NTD, epilepsy, DM) | 5 mg/day | 3 months pre-conception + 1st trim | NICE / FOGSI |
| Megaloblastic anaemia (folate) | 5 mg/day | 4 months | BNF / WHO |
| Haemolytic anaemia prophylaxis | 5 mg/week | Ongoing | BNF |
| Haemodialysis | 5 mg 3× weekly (post-dialysis) | Ongoing | KDIGO |
| Low-dose MTX (RA / psoriasis) | 5 mg once weekly (24–48h after MTX) | Throughout MTX therapy | BSR / ACR |
| High-dose MTX rescue (folinic acid) | 15 mg IV/oral q6h × 8 doses | Starting 24h after MTX | Oncology protocol |
| Paediatric folate deficiency | 0.1 mg/kg/day (max 5mg) | 4 months | BNFC / IAP |